-
Mashup Score: 3
A genomic investigation of 3,600 small cell lung cancer (SCLC) tumors reveals novel rare cohorts with potential therapeutic importance, biopsy site–specific heterogeneity, and new insights into SCLC histologic transformation.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
AbstractBackground:. Animal and experimental studies suggest circadian disruption increases colorectal cancer risk, but evidence in humans is limited. We examined night shift work, chronotype, and residential position within a time zone, proxies for circadian disruption, in relation to colorectal cancer risk.Methods:. Participants in the Black Women’s Health Study, a prospective cohort of 59,000…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Does circadian disruption increase #ColorectalCancer risk? Barber et al examine night shift work, chronotype, and residential position within a time zone and find that long duration of night-shift work may increase risk in black women. https://t.co/n93Hol0cu9 https://t.co/ai1clgmXcF
-
-
Mashup Score: 1Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma. - 2 year(s) ago
Abstract. Purpose: Chromosome 1 (chr1) copy number abnormalities (CNAs) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and associate with a heterogeneous impact on outcome the drivers of which are largely unknown. Experimental Design: A multiomic approach comprising CRISPR, gene mapping of CNA and SV, methylation, expression, and mutational analysis was used…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma @DrGarethMorgan1 #mmsm https://t.co/cBMi7TznlB
-
-
Mashup Score: 0
AbstractPurpose:. Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical trial in patients with advanced biliary tract cancer (BTC).Patients and Methods:. Cell viability assays of devimistat ± gemcitabine and cisplatin (GC) were performed and the effect of devimistat on mitochondrial respiration…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @CCR_AACR: Devimistat in biliary cancer. https://t.co/dHYY4utvGH https://t.co/aeO94xjOE8
-
-
Mashup Score: 0ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma - 2 year(s) ago
PI3K/Akt signaling promotes metabolic adaptation to ONC201-mediated disruption of mitochondrial energy homeostasis in diffuse intrinsic pontine glioma, highlighting the utility of a combination treatment strategy using ONC201 and the PI3K/Akt inhibitor paxalisib.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read the article behind the current cover— ONC201 in combination with Paxalisib for the treatment of H3K27-altered diffuse midline #glioma, by @MattDun17 et al. https://t.co/0wXpGGmSHv @Uni_Newcastle https://t.co/W9Pnmg4d4p
-
-
Mashup Score: 0Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC - 2 year(s) ago
Genetic coalterations in KEAP1, SMARCA4, and CDKN2A were revealed as major independent determinants of KRASG12C inhibitor clinical outcomes in advanced non–small cell lung cancer that together allow for patient segregation into prognostic subgroups.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the July issue— Co-mutations and #KRAS G12C Inhibitor Efficacy in Advanced Non-Small Cell #LungCancer, by @FSkoulidis et al. https://t.co/kob79IsKvU @MDAndersonNews #lcsm #NSCLC https://t.co/1tjjzHWoxp
-
-
Mashup Score: 0Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study - 2 year(s) ago
AbstractBackground:. Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma are sparse.Methods:. We performed a Swedish population-based cohort study over 1993 to 2019 to delineate differences in incidence and survival in early-onset (age 20–54 years) compared with later-onset (55–99 years) esophageal, cardia, and noncardia…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early-onset #adenocarcinomas are increasing in high-income countries. Comparison of early & later-onset Esophagogastric Adenocarcinoma in Sweden finds no major differences in incidence trends. Survival was better in early-onset cancer patients. https://t.co/JymNQ6v2bg
-
-
Mashup Score: 1
AbstractPurpose:. We describe the clinical and genomic landscape of the non–small cell lung cancer (NSCLC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC).Experimental Design:. A total of 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions…
Categories: Hem/Oncs, Latest HeadlinesTweet-
The @AACR GENIE BPC is an impressive resource with 1846 annotated NSCLC cases with NGS from 2014-18, described @CCR_AACR. In this dataset, 44% had an actionable alteration (20% #EGFR, 13% #KRAS G12C). Free access to explore! @NouraChoudhury @RielyMD https://t.co/2kGkYVpA6i
-
-
Mashup Score: 6In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies - 2 year(s) ago
AbstractChimeric antigen receptor (CAR) T therapies hold immense promise to revolutionize cancer treatment. Nevertheless, key challenges, primarily in solid tumor settings, continue to hinder the application of this technology. Understanding CAR T-cell mechanism of action, in vivo activity, and clinical implications is essential for harnessing its full therapeutic potential. Single-cell genomics…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the July issue— In Synergy: Optimizing CAR-T development and personalizing patient care using #singlecell technologies, by @orenbarboy, Yonatan Katzenelenbogen, @Rotem_Shalita, and @IdoAmitLab. https://t.co/ZF6nmqR1Sf @WeizmannScience https://t.co/v1akJDD1KK
-
-
Mashup Score: 3
NF-κB activation in hepatocytes with low RIPK3 expression can trigger sublethal necrosome activation.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this week's Cancer Discovery #ResearchWatch: Hepatocarcinogenesis Is Supported by Sublethal Necroptosis Signaling, summarizing the work of Mihael Vucur, @tom_luedde et al. https://t.co/yfbYjvXUM6 @UniklinikDUS https://t.co/VC1nnx9vEu
-
July issue— Integrative Analysis of a Large Real-world Cohort of #SmallCellLungCancer Identifies Distinct Genetic Subtypes & Insights into Histological Transformation, @smruthy90, @SageJulien, @christine_lovly et al. https://t.co/SezbqmNMIx @FoundationATCG @Stanford @VUMC_Cancer https://t.co/W9HwPSODX5